Design Therapeutics, Inc.
DSGNNext catalyst
ALECENSA - alectinib hydrochloride capsule
ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Get an email about DSGN's next catalysts
Track Design Therapeutics (DSGN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (Phase 2 readout).See the timeline
2 upcoming, 2 past
ALECENSA - alectinib hydrochloride capsule Phase 3 Est. Readout (Drugs-SNPs)
Estimated primary completion for ALECENSA - alectinib hydrochloride capsule trial (NCT05987956) in ALK-Positive Non-Small Cell Lung Cancer (NSCLC). Topline data typically follows completion by weeks to months.
SourceDT-216P2 Phase 2 Est. Readout
Primary completion for DT-216P2 trial (NCT06874010) in Friedreich Ataxia
SourceHow DSGN's past catalysts played out
Market Overview
Stock performance and key metrics
ALECENSA - alectinib hydrochloride capsule
ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
DT-216P2
Friedreich Ataxia
DT-168
Fuchs Endothelial Corneal Dystrophy
Combination of MK3475 with Metronomic CP
Sarcoma
Combination of MK3475 with Metronomic CP and G100
Sarcoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ALECENSA - alectinib hydrochloride capsule | Phase 3 | ALK-Positive Non-Small Cell Lung Cancer (NSCLC) | - | - |
DT-216P2 | Phase 2 | Friedreich Ataxia | - | - |
DT-168 | Phase 2 | Fuchs Endothelial Corneal Dystrophy | - | - |
Combination of MK3475 with Metronomic CP | Phase 2 | Sarcoma | - | - |
Combination of MK3475 with Metronomic CP and G100 | Phase 2 | Sarcoma | - | - |
Frequently asked questions
What is in Design Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Design Therapeutics, Inc.'s (DSGN) pipeline across Phase 3, Phase 2. Its lead program is ALECENSA - alectinib hydrochloride capsule (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Design Therapeutics, Inc.'s next FDA catalyst?→
Design Therapeutics, Inc.'s (DSGN) next tracked catalyst is a Phase 3 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DSGN biotech catalysts?→
Add DSGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Design Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.